Novel pharmacological treatments for children and adolescents with heterozygous familial hypercholesterolemia.

about

Novel pharmacological treatments for children and adolescents with heterozygous familial hypercholesterolemia.

Item

http://www.wikidata.org/entity/Q40102570

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Novel pharmacological treatmen ...... familial hypercholesterolemia.

@en

type

Item

label

Novel pharmacological treatmen ...... familial hypercholesterolemia.

@en

prefLabel

Novel pharmacological treatmen ...... familial hypercholesterolemia.

@en

P1476

Novel pharmacological treatmen ...... familial hypercholesterolemia.

@en

P2093

Albert Wiegman

http://www.w3.org/2001/XMLSchema#string

Barbara A Hutten

http://www.w3.org/2001/XMLSchema#string

P2860

Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia.

Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment.

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.

Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies.

Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery dis

Efficacy and Safety of Pitavastatin in Children and Adolescents at High Future Cardiovascular Risk.

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.

P304

919-921

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1080/17512433.2017.1362333

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28756723

http://www.w3.org/2001/XMLSchema#string

P921

hypercholesterolemia